ARTL

Artelo Biosciences, Inc.

ARTL · CIK 1621221 · Annual (10-K) · Last 8 years

Financial Trends

Revenue
20182025
Net Income−$13M
20182025
Operating CF−$9M
20182025
Free Cash Flow
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue————————
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
SG&A Expense————————
Operating Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Net Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)——————$-1.00—
EPS (Diluted)$-12.52$-3.05————$-1.46—

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Assets$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cash & Equivalents$0.0B——$0.0B$0.0B$0.0B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B———
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$-0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$-0.0B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$-0.0B$0.0B$0.0B$0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Capital Expenditures————————
Financing Cash Flow$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
← Companies